



Viracor-IBT partners with The National Kidney Registry to accelerate living donor transplantation

14 August 2015

Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services, is pleased to announce a partnership between The National Kidney Registry (NKR) and Viracor-IBT Laboratories, a wholly-owned subsidiary of Eurofins, to streamline pre-transplant serology testing for kidney donors. The NKR selected Viracor-IBT as the national laboratory to perform infectious disease screening for its 75 member centers. Fast and accurate preoperative serology testing reduces paired kidney exchange or “swap” failures and increases the number of patients transplanted in NKR facilitated swaps. With so many lives involved, time is of the essence and streamlined logistics are critical; delayed test results can delay transplants.

In describing the selection of Viracor-IBT for national laboratory services, Garet Hil, Founder and CEO of the NKR said, “Infectious disease screening is a critical part of the paired exchange process. These tests need to be fast and accurate; otherwise swaps can be delayed, or worse, cancelled. Through our partnership with Viracor-IBT we further streamline the pre-op serology testing process, reducing the turnaround for these tests to under two days from as much as 10 days, while providing secure electronic transmission of the results.”

Julie Kliegl, President of Viracor-IBT added, “Like the NKR, Viracor-IBT is passionate about helping transplant patients. As a laboratory committed to providing test results faster when it matters most, Viracor-IBT is thrilled to partner with the NKR on this critical program that accelerates donor-recipient matching and increases living donor transplantation.”

The NKR and Viracor-IBT are continually working together to identify additional areas in which this collaboration can benefit transplant donors, recipients and hospital services.

For more information please visit <http://www.eurofins.com> or contact:

Viracor-IBT
Jenni Miller, Corporate Communications
Phone: +1 800 305 5198
E-mail: jenni.miller@viracoribt.com

Eurofins Scientific
Investor Relations
Phone: +32 2 766 1620
E-mail: ir@eurofins.com

Notes for the editor:

About National Kidney Registry

The National Kidney Registry (www.kidneyregistry.org) is a nonprofit organization with the mission to save and improve the lives of people facing kidney failure by increasing the quality, speed, and number of living donor transplants.

Eurofins – a global leader in bio-analysis

Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agrosience, genomics, discovery pharmacology and central laboratory services.

With about 19,000 staff in more than 200 laboratories across 38 countries, Eurofins offers a portfolio of over 130,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products. The Group provides its customers with high-quality services, accurate results on time and

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.